Pharmaceutical Cannabis - Netherlands

Netherlands

Revenue in the Pharmaceutical Cannabis is projected to reach US$28.29m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 4.75%, resulting in a market volume of US$35.68m by 2029.
In global comparison, most revenue will be generated in the United States (US$913.10m in 2024).
In relation to total population figures, per person revenues of US$4.50k are generated in 2024.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceutical Cannabis market in Netherlands has been experiencing significant growth and development in recent years.

Customer preferences: Customers in the Netherlands are increasingly turning to Pharmaceutical Cannabis products due to the growing awareness of its potential health benefits and therapeutic properties. The shift towards natural and alternative medicines has driven demand for Pharmaceutical Cannabis products among a wide range of consumers.

Trends in the market: One key trend in the Pharmaceutical Cannabis market in Netherlands is the increasing acceptance and legalization of medical cannabis. This has opened up opportunities for pharmaceutical companies to develop and market a variety of cannabis-based products to cater to the growing demand. Additionally, the Netherlands has a long history of cannabis tolerance, which has created a favorable environment for the growth of the Pharmaceutical Cannabis market.

Local special circumstances: The Netherlands has a well-established reputation for its expertise in horticulture and agricultural practices, which has positioned the country as a hub for cannabis cultivation and research. This has attracted both domestic and international players to invest in the Pharmaceutical Cannabis market in the country. Furthermore, the Dutch government has implemented progressive policies and regulations surrounding the use of medical cannabis, further fueling market growth.

Underlying macroeconomic factors: The Netherlands has a stable economy and a strong healthcare system, which has contributed to the growth of the Pharmaceutical Cannabis market. Additionally, the country's strategic location and well-developed infrastructure make it an attractive market for pharmaceutical companies looking to expand their presence in Europe. The increasing investment in research and development of Pharmaceutical Cannabis products also indicates a positive outlook for the market in the Netherlands.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.